Trump Moves to Boost Research on Psychedelic Drug for PTSD

The Trump administration is preparing to sign an executive order aimed at expanding U.S. research into ibogaine, a psychedelic substance being explored as a treatment for post-traumatic stress disorder (PTSD) and other mental health conditions.

Sources say the order could be signed as early as this week and would signal federal interest in studying the drug’s safety and effectiveness—particularly for veterans suffering from PTSD and traumatic brain injuries.

Ibogaine is a naturally occurring compound derived from an African shrub. It has been used in some countries to treat conditions such as addiction, anxiety, depression, and trauma. However, it remains illegal in the United States and is classified as a Schedule I substance, meaning it is considered to have no accepted medical use and a high potential for abuse.

Because of this restriction, some Americans have traveled abroad—often to clinics in Mexico or the Caribbean—to access ibogaine treatments. These facilities typically operate without U.S. regulatory oversight, raising concerns about safety standards and monitoring.

While the planned executive order would not change ibogaine’s legal status, it is expected to open pathways for federally funded research. Officials say the goal is to determine whether the drug is a legitimate medical breakthrough or an unproven therapy.

Interest in ibogaine has been growing. Texas recently committed $50 million toward research, and small studies have suggested it may help reduce symptoms of PTSD, addiction cravings, and depression. One study involving veterans reported improvements when ibogaine was combined with magnesium to reduce heart-related risks.

Still, experts caution that current evidence is limited. Most studies so far are small, and only one rigorous clinical trial has been completed. Larger, controlled trials are now beginning.

Safety remains a major concern. Ibogaine has been linked to serious heart complications, including fatal rhythm disturbances. A 2023 review found that while the drug showed promise in reducing withdrawal symptoms, the risk of toxicity and death was significant, with at least 27 reported fatalities associated with its use.

Researchers emphasize that more data is needed before ibogaine can be considered a safe or effective treatment. The administration’s move could help accelerate that process, but key questions about risks, regulation, and real-world benefits remain unresolved.